Report Detail

Pharma & Healthcare Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2019

  • RnM3199182
  • |
  • 18 March, 2020
  • |
  • Global
  • |
  • 78 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Severe Acute Respiratory Syndrome (SARS) - Overview

              Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development

                                      AIM ImmunoTech Inc

                                        Atriva Therapeutics GmbH

                                          Autoimmune Technologies LLC

                                            Biotron Ltd

                                              CEL-SCI Corp

                                                Fab’entech SA

                                                  GeneCure LLC

                                                    Gilead Sciences Inc

                                                      Global BioLife Inc Ltd

                                                        Novavax Inc

                                                          Oncovir Inc

                                                            Phelix Therapeutics LLC

                                                              Sagimet Biosciences

                                                                Sirnaomics Inc

                                                                  Suzhou Ribo Life Sciences Co Ltd

                                                                    Severe Acute Respiratory Syndrome (SARS) - Drug Profiles

                                                                      Antisense RNAi Oligonucleotide for Severe Acute Respiratory Syndrome - Drug Profile

                                                                        Product Description

                                                                          Mechanism Of Action

                                                                            R&D Progress

                                                                              Antisense RNAi Oligonucleotides for Severe Acute Respiratory Syndrome - Drug Profile

                                                                                Product Description

                                                                                  Mechanism Of Action

                                                                                    R&D Progress

                                                                                      ATR-006 - Drug Profile

                                                                                        Product Description

                                                                                          Mechanism Of Action

                                                                                            R&D Progress

                                                                                              CEL-1000 - Drug Profile

                                                                                                Product Description

                                                                                                  Mechanism Of Action

                                                                                                    R&D Progress

                                                                                                      CSW-1 - Drug Profile

                                                                                                        Product Description

                                                                                                          Mechanism Of Action

                                                                                                            R&D Progress

                                                                                                              Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile

                                                                                                                Product Description

                                                                                                                  Mechanism Of Action

                                                                                                                    R&D Progress

                                                                                                                      FDX-000 - Drug Profile

                                                                                                                        Product Description

                                                                                                                          Mechanism Of Action

                                                                                                                            R&D Progress

                                                                                                                              LB-2 - Drug Profile

                                                                                                                                Product Description

                                                                                                                                  Mechanism Of Action

                                                                                                                                    R&D Progress

                                                                                                                                      ML-188 - Drug Profile

                                                                                                                                        Product Description

                                                                                                                                          Mechanism Of Action

                                                                                                                                            R&D Progress

                                                                                                                                              Monoclonal Antibody for SARS Virus Infections - Drug Profile

                                                                                                                                                Product Description

                                                                                                                                                  Mechanism Of Action

                                                                                                                                                    R&D Progress

                                                                                                                                                      Poly-ICLC - Drug Profile

                                                                                                                                                        Product Description

                                                                                                                                                          Mechanism Of Action

                                                                                                                                                            R&D Progress

                                                                                                                                                              remdesivir - Drug Profile

                                                                                                                                                                Product Description

                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                    R&D Progress

                                                                                                                                                                      rintatolimod - Drug Profile

                                                                                                                                                                        Product Description

                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                            R&D Progress

                                                                                                                                                                              SARS (virus like particle) vaccine - Drug Profile

                                                                                                                                                                                Product Description

                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                      severe acute respiratory syndrome vaccine - Drug Profile

                                                                                                                                                                                        Product Description

                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                              severe acute respiratory syndrome vaccine - Drug Profile

                                                                                                                                                                                                Product Description

                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                      Small Molecule to Inhibit Coronavirus E Protein for Severe Acute Respiratory Syndrome - Drug Profile

                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                              SSYA-10001 - Drug Profile

                                                                                                                                                                                                                Product Description

                                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                                      TVB-3567 - Drug Profile

                                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                                              Severe Acute Respiratory Syndrome (SARS) - Dormant Projects

                                                                                                                                                                                                                                Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones

                                                                                                                                                                                                                                  Featured News & Press Releases

                                                                                                                                                                                                                                    Feb 04, 2020: Gilead’s remdesivir to enter trials for coronavirus treatment

                                                                                                                                                                                                                                      Aug 04, 2014: Hemispherx's Two Drugs, Ampligen and Alferon Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses

                                                                                                                                                                                                                                        Appendix

                                                                                                                                                                                                                                          Methodology

                                                                                                                                                                                                                                            Coverage

                                                                                                                                                                                                                                              Secondary Research

                                                                                                                                                                                                                                                Primary Research

                                                                                                                                                                                                                                                  Expert Panel Validation

                                                                                                                                                                                                                                                    Contact Us

                                                                                                                                                                                                                                                      Disclaimer

                                                                                                                                                                                                                                                      Summary:
                                                                                                                                                                                                                                                      Get latest Market Research Reports on Severe Acute Respiratory Syndrome (SARS). Industry analysis & Market Report on Severe Acute Respiratory Syndrome (SARS) is a syndicated market report, published as Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2019. It is complete Research Study and Industry Analysis of Severe Acute Respiratory Syndrome (SARS) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                                                                                      Last updated on

                                                                                                                                                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                                                      Purchase this Report

                                                                                                                                                                                                                                                      $2,000.00
                                                                                                                                                                                                                                                      $4,000.00
                                                                                                                                                                                                                                                      $6,000.00
                                                                                                                                                                                                                                                      1,584.00
                                                                                                                                                                                                                                                      3,168.00
                                                                                                                                                                                                                                                      4,752.00
                                                                                                                                                                                                                                                      1,852.00
                                                                                                                                                                                                                                                      3,704.00
                                                                                                                                                                                                                                                      5,556.00
                                                                                                                                                                                                                                                      302,700.00
                                                                                                                                                                                                                                                      605,400.00
                                                                                                                                                                                                                                                      908,100.00
                                                                                                                                                                                                                                                      166,800.00
                                                                                                                                                                                                                                                      333,600.00
                                                                                                                                                                                                                                                      500,400.00
                                                                                                                                                                                                                                                      Credit card Logo

                                                                                                                                                                                                                                                      Related Reports


                                                                                                                                                                                                                                                      Reason to Buy

                                                                                                                                                                                                                                                      Request for Sample of this report